Compare GNPX & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNPX | COSM |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 13.5M |
| IPO Year | 2017 | 2009 |
| Metric | GNPX | COSM |
|---|---|---|
| Price | $0.86 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 732.3K | ★ 1.3M |
| Earning Date | 05-11-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.15 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $65,271,815.00 |
| Revenue This Year | N/A | $54.08 |
| Revenue Next Year | N/A | $32.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.93 |
| 52 Week Low | $0.14 | $0.28 |
| 52 Week High | $12.97 | $1.32 |
| Indicator | GNPX | COSM |
|---|---|---|
| Relative Strength Index (RSI) | 20.65 | 50.20 |
| Support Level | $0.15 | $0.35 |
| Resistance Level | $2.12 | $0.41 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 1.25 | 45.15 |
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.